Influence of Additional Cytogenetic Abnormalities on Outcome in AML
| Abnormality . | No. of Patients . | CR Rate % . | Relapse Risk at 3 yr % (SE) . | Overall Survival at 3 yr % (SE) . |
|---|---|---|---|---|
| Normal | 680 | 88 | 49 (2.2) | 45 (1.9) |
| t(15;17) | 198 | |||
| Alone | 137 | 88 | 30 (4.5) | 69 (3.9) |
| +8 | 31 | 84 | 40 (9.9) | 71 (8.3) |
| Other | 30 | 90 | 32 (10.1) | 66 (8.7) |
| t(8;21) | 122 | |||
| Alone | 49 | 96 | 31 (7.3) | 67 (6.7) |
| −X/−Y | 57 | 98 | 25 (6.1) | 77 (5.6) |
| Other | 16 | 100 | 30 (12.6) | 63 (12.1) |
| inv(16) | 57 | |||
| Alone | 35 | 89 | 43 (9.0) | 63 (8.2) |
| Other | 22 | 86 | 24 (10.5) | 64 (10.3) |
| +8 | 148 | |||
| Alone | 48 | 83 | 42 (8.4) | 42 (7.1) |
| Favorable | 43 | 88 | 32 (7.7) | 77 (6.5)* |
| Adverse | 20 | 70 | 50 (13.45) | 50 (11.2) |
| Other | 43 | 91 | 44 (8.8) | 51 (7.6) |
| 11q23 | 60 | |||
| t(9;11)(p22;q23) | 18 | 89 | 35 (12.6) | 50 (11.8) |
| t(10;11)(p12;q23) | 12 | 83 | 77 (14.3) | 17 (10.8) |
| Other | 30 | 87 | 43 (9.8) | 53 (9.1) |
| del(7q) | 32 | |||
| Adverse | 17 | 65 | 69 (14.7) | 24 (10.3) |
| Alone/other | 15 | 87 | 50 (14.4) | 32 (12.2) |
| del(9q) | 25 | |||
| Alone | 6 | 100 | 37 (21.3) | 50 (20.4) |
| t(8;21) | 9 | 100 | 12 (11.7) | 89 (10.5) |
| Other | 10 | 100 | 60 (15.5) | 50 (15.8) |
| +22 | 22 | |||
| Alone | 1 | 100 | 100 (0.0) | 100 (0.0) |
| Adverse | 4 | 100 | 75 (21.7) | 25 (21.7) |
| Other | 17 | 88 | 29 (12.5) | 65 (11.6) |
| −7 | 61 | |||
| Alone | 15 | 60 | 70 (16.4) | 13 (8.8) |
| Other adverse | 30 | 50 | 87 (8.8) | 7 (4.6) |
| Other | 16 | 56 | 78 (13.9) | 19 (9.8) |
| Other numerical | 219 | |||
| Alone | 35 | 80 | 43 (11.0) | 40 (8.3) |
| Favorable | 25 | 92 | 32 (10.8) | 64 (9.6) |
| Adverse | 102 | 65 | 74 (5.7)* | 18 (3.8) |
| Other | 66 | 85 | 51 (7.2) | 39 (6.0) |
| Other structural | 366 | |||
| Alone | 117 | 76 | 45 (5.5) | 43 (4.6) |
| Favorable | 47 | 89 | 34 (7.7) | 66 (6.9)* |
| Adverse | 115 | 65 | 71 (5.5)† | 19 (3.7)† |
| Other | 95 | 84 | 50 (6.0) | 40 (5.1) |
| abn(3q) | 40 | |||
| Alone | 14 | 79 | 80 (12.6) | 29 (12.1) |
| −7 | 11 | 45 | 100 (0.0) | 0 (0.0) |
| Other | 15 | 60 | 84 (14.2) | 20 (10.3) |
| del(5q) | 28 | |||
| Alone | 5 | 100 | 100 (0.0) | 0 (0.0) |
| Complex | 16 | 50 | 85 (13.8) | 6 (6.1) |
| Other | 7 | 43 | 67 (27.2) | 29 (17.1) |
| −5 | 26 | |||
| Alone | 0 | — | — | — |
| Other adverse | 22 | 41 | 87 (12.1) | 5 (4.4) |
| Other | 4 | 50 | 100 (0.0) | 0 (0.0) |
| Abnormality . | No. of Patients . | CR Rate % . | Relapse Risk at 3 yr % (SE) . | Overall Survival at 3 yr % (SE) . |
|---|---|---|---|---|
| Normal | 680 | 88 | 49 (2.2) | 45 (1.9) |
| t(15;17) | 198 | |||
| Alone | 137 | 88 | 30 (4.5) | 69 (3.9) |
| +8 | 31 | 84 | 40 (9.9) | 71 (8.3) |
| Other | 30 | 90 | 32 (10.1) | 66 (8.7) |
| t(8;21) | 122 | |||
| Alone | 49 | 96 | 31 (7.3) | 67 (6.7) |
| −X/−Y | 57 | 98 | 25 (6.1) | 77 (5.6) |
| Other | 16 | 100 | 30 (12.6) | 63 (12.1) |
| inv(16) | 57 | |||
| Alone | 35 | 89 | 43 (9.0) | 63 (8.2) |
| Other | 22 | 86 | 24 (10.5) | 64 (10.3) |
| +8 | 148 | |||
| Alone | 48 | 83 | 42 (8.4) | 42 (7.1) |
| Favorable | 43 | 88 | 32 (7.7) | 77 (6.5)* |
| Adverse | 20 | 70 | 50 (13.45) | 50 (11.2) |
| Other | 43 | 91 | 44 (8.8) | 51 (7.6) |
| 11q23 | 60 | |||
| t(9;11)(p22;q23) | 18 | 89 | 35 (12.6) | 50 (11.8) |
| t(10;11)(p12;q23) | 12 | 83 | 77 (14.3) | 17 (10.8) |
| Other | 30 | 87 | 43 (9.8) | 53 (9.1) |
| del(7q) | 32 | |||
| Adverse | 17 | 65 | 69 (14.7) | 24 (10.3) |
| Alone/other | 15 | 87 | 50 (14.4) | 32 (12.2) |
| del(9q) | 25 | |||
| Alone | 6 | 100 | 37 (21.3) | 50 (20.4) |
| t(8;21) | 9 | 100 | 12 (11.7) | 89 (10.5) |
| Other | 10 | 100 | 60 (15.5) | 50 (15.8) |
| +22 | 22 | |||
| Alone | 1 | 100 | 100 (0.0) | 100 (0.0) |
| Adverse | 4 | 100 | 75 (21.7) | 25 (21.7) |
| Other | 17 | 88 | 29 (12.5) | 65 (11.6) |
| −7 | 61 | |||
| Alone | 15 | 60 | 70 (16.4) | 13 (8.8) |
| Other adverse | 30 | 50 | 87 (8.8) | 7 (4.6) |
| Other | 16 | 56 | 78 (13.9) | 19 (9.8) |
| Other numerical | 219 | |||
| Alone | 35 | 80 | 43 (11.0) | 40 (8.3) |
| Favorable | 25 | 92 | 32 (10.8) | 64 (9.6) |
| Adverse | 102 | 65 | 74 (5.7)* | 18 (3.8) |
| Other | 66 | 85 | 51 (7.2) | 39 (6.0) |
| Other structural | 366 | |||
| Alone | 117 | 76 | 45 (5.5) | 43 (4.6) |
| Favorable | 47 | 89 | 34 (7.7) | 66 (6.9)* |
| Adverse | 115 | 65 | 71 (5.5)† | 19 (3.7)† |
| Other | 95 | 84 | 50 (6.0) | 40 (5.1) |
| abn(3q) | 40 | |||
| Alone | 14 | 79 | 80 (12.6) | 29 (12.1) |
| −7 | 11 | 45 | 100 (0.0) | 0 (0.0) |
| Other | 15 | 60 | 84 (14.2) | 20 (10.3) |
| del(5q) | 28 | |||
| Alone | 5 | 100 | 100 (0.0) | 0 (0.0) |
| Complex | 16 | 50 | 85 (13.8) | 6 (6.1) |
| Other | 7 | 43 | 67 (27.2) | 29 (17.1) |
| −5 | 26 | |||
| Alone | 0 | — | — | — |
| Other adverse | 22 | 41 | 87 (12.1) | 5 (4.4) |
| Other | 4 | 50 | 100 (0.0) | 0 (0.0) |
OS and RR are quoted at 3 years, as relatively small numbers restrict the reliability of 5-year values.
P < .01.
P < .001: P values are for log rank test, comparing the outcome of groups in the presence or absence of an additional cytogenetic abnormality. Outcome is also shown for patients with the two most common translocations involving 11q23, as well as for the remaining patients with other rearrangements disrupting 11q23, irrespective of the presence of additional cytogenetic changes.